

### IN THE CLAIMS

Please amend the claims as follows:

1-13. (Canceled)

14. (Currently Amended) A therapeutic method for treating a bone-associated cancer in a human patient comprising:

(a) parenterally administering a dose of  $^{153}\text{Sm}$ -EDTMP by intravenous infusion or injection in an aqueous vehicle comprising an effective antiradiolytic amount of pharmaceutically acceptable radio protectant;

(b) administering a dose of about 140-200 mg/m<sup>2</sup> of melphalan to said patients, wherein steps (a) and/or (b) are effective to suppress the bone marrow of a human patient; and

(c) providing the patient with bone marrow transplantation and/or restoration; wherein the patient is not subjected to total body irradiation in conjunction with the therapeutic method.

15. (Previously Presented) The method of claim 14 wherein step (c) is carried out while the bone marrow is suppressed by steps (a) and (b).

16. (Previously Presented) The method of claim 14 wherein the patient is refractory to treatment or in relapse after treatment with chemotherapy and/or total body irradiation.

17. (Previously Presented) The method of claim 14 wherein the patient is hydrated prior to, during and/or after step (a).

18. (Previously Presented) The method of claim 14, 15 or 16, wherein the bone-associated cancer is multiple myeloma.

19. (Previously Presented) The method of claim 14 wherein the bone marrow transplantation or restoration comprises bone marrow transplantation, stem cell transplantation and/or administration of a colony stimulating factor.

20. (Cancelled)
21. (Currently Amended) The method of claim ~~20~~ 14, 15, 16 or 17 wherein the radioprotectant is an ascorbate or gentisic acid.
22. (Previously Presented) The method of claim 21 wherein the ascorbate is ascorbic acid at a concentration of about 35-75 mg/ml.
23. (Previously Presented) The method of claim 14, 15, 16 or 17 wherein the dose delivers about 30-40 Gy of radiation to the bone marrow of the patient.
24. (Previously Presented) The method of claim 14, 15, 16 or 17 wherein the dose delivers about 15-30 Gy of radiation to the bone marrow of the patient.
25. (Previously Presented) The method of claim 14, 15, 16 or 17 wherein about 200 mg/m<sup>2</sup> of melphalan is administered.
26. (Cancelled)
27. (Cancelled)
28. (Cancelled)
29. (Cancelled)
30. (Cancelled)
31. (Cancelled)
32. (Cancelled)

33. (Cancelled)

34. (Cancelled)

35. (Previously Presented) The method of claim 14 wherein the cancer is metastatic breast cancer.